| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 07/01/2025 | 23:18 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 23/12/2024 | 22:15 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 14/11/2024 | 14:03 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 26/09/2024 | 22:36 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 07/11/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 03/11/2023 | 21:05 | GlobeNewswire Inc. | Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 01/11/2023 | 12:30 | GlobeNewswire Inc. | Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 25/10/2023 | 15:05 | GlobeNewswire Inc. | Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 23/10/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023 | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 27/09/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo® | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 21/09/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 13/09/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunot | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 30/08/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics to Participate in Upcoming Investor Conferences | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 17/08/2023 | 23:15 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 03/08/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 02/08/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 27/06/2023 | 15:01 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 15/06/2023 | 22:41 | Edgar (US Regulatory) | Annual Report to Security Holders (ars) | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 15/06/2023 | 22:32 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 02/06/2023 | 23:04 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 01/06/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 23/05/2023 | 22:31 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 09/05/2023 | 22:34 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 09/05/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 01/05/2023 | 22:19 | Edgar (US Regulatory) | Amended Annual Report (10-k/a) | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 20/04/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 18/04/2023 | 22:05 | GlobeNewswire Inc. | Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023 | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 13/04/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 30/03/2023 | 13:30 | GlobeNewswire Inc. | Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
| 29/03/2023 | 23:18 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) | NASDAQ:SNSE | Sensei Biotherapeutics Inc |
